These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30049576)

  • 1. [What primary care physicians should know about new markers in prostate cancer].
    Jalón Monzón A; Alvarez Múgica M; Jalón Monzón M; Escaf Barmadah S
    Semergen; 2018 Sep; 44(6):430-438. PubMed ID: 30049576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current aspects of prostate cancer screening].
    Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
    Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
    Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
    Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
    Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
    Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for evaluation of prostate cancer prognosis.
    Esfahani M; Ataei N; Panjehpour M
    Asian Pac J Cancer Prev; 2015; 16(7):2601-11. PubMed ID: 25854335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Specificity of PSA Screening with Serum and Urine Markers.
    Kearns JT; Lin DW
    Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for early prostate cancer detection.
    Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
    Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA density improves prediction of prostate cancer.
    Verma A; St Onge J; Dhillon K; Chorneyko A
    Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
    Shen X; Kumar P
    J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.